Epigenomic Priming as an Immunotherapy Enhancer in Ovarian Cancer
Technical Report,01 May 2018,30 Apr 2019
Northwestern University Evanston United States
Pagination or Media Count:
New immunologic approaches targeting immune checkpoint pathways, such as the programmed cell death protein-1 PD-1 are under clinical development for solid tumors, including ovarian cancer OC. Anti-PD1 strategies prevent T-cell exhaustion, augmenting immune anti-tumor responses. The focus of this application is to develop a combination regimen that enhances the activity of PD1-targeted immunotherapy in a clinical trial designed for women with recurrent ovarian cancer. We speculate that an important mechanism of immune evasion in OC is represented by epigenetic silencing of tumor antigens. One of the mechanisms of transcriptional repression of tumor antigens.
- Medicine and Medical Research